Haisco Pharmaceutical discovers PI3Kα inhibitors for breast cancer
July 11, 2024
Haisco Pharmaceutical Group Co. Ltd. has identified phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of breast cancer.
